

Attend these presentations during the 64th ASH annual meeting to see how NGS is advancing hemato-oncology studies

Umbrella trial in myeloid malignancies: the MyeloMATCH National Clinical Trials Network precision medicine initiative

Number: 4080

Presenter: Richard Little

Session: 616. Acute myeloid leukemias: investigational therapies, excluding transplantation and cellular immunotherapies: Poster III

Time and location: Monday, December 12, 2022:

6:00–8:00 p.m., Hall D (Ernest N. Morial Convention Center)

Clinical features and mutational landscape of patients referred for suspected essential thrombocythosis: a descriptive study using a real-world database

Number: 3546

Presenter: Ala Almanaseer

Session: 903. Health services and quality—myeloid malignancies: Poster II

Time and location: Sunday, December 11, 2022:

6:00–8:00 p.m., Hall D (Ernest N. Morial Convention Center)

Bone marrow microenvironment changes in myelodysplastic neoplasms and their relationship with clonal hematopoiesis and disease progression

Number: 1751

Presenter: Antonietta Molero Yordi

Session: 636. Myelodysplastic syndromes—basic and translational: Poster I

Time and location: Saturday, December 10, 2022:

5:30–7:30 p.m., Hall D (Ernest N. Morial Convention Center)

Impact of higher calreticulin gene mutation variant allele frequency in patients with myelofibrosis

Number: 1720

Presenter: Chiara Maccari

Session: 634. Myeloproliferative syndromes: clinical and epidemiological: Poster I

Time and location: Saturday, December 10, 2022:

5:30–7:30 p.m., Hall D (Ernest N. Morial Convention Center)



Acute myeloid leukemia (AML) risk stratification using the European LeukemiaNet 2022 Classification in a real-life cohort of patients from Sardinia, Italy

Number: 4126

Presenter: Giovanna Piras

Session: 617. Acute myeloid leukemias: biomarkers, molecular markers, and minimal residual disease in diagnosis and prognosis: Poster III

Time and location: Monday, December 12, 2022:

6:00–8:00 p.m., Hall D (Ernest N. Morial Convention Center)

SF3B1, RUNX1, and TP53 mutations significantly impact the outcome of patients with lower-risk myelodysplastic syndrome

Number: 3077

Presenter: Jose Falantes

Session: 637. Myelodysplastic syndromes—clinical and epidemiological: Poster II

Time and location: Sunday, December 11, 2022:

6:00–8:00 p.m., Hall D (Ernest N. Morial Convention Center)

Longitudinal profiling of the T cell compartment in patients with chronic lymphocytic leukemia treated with venetoclax

Number: 4440

Presenter: Elisavet Vlachonikola

Session: 642. Chronic lymphocytic leukemia: clinical and epidemiological: Poster III

Time and location: Monday, December 12, 2022:

6:00–8:00 PM, Hall D (Ernest N. Morial Convention Center)

Evolutionary portrait of adult core-binding factor leukemia patients treated with a continuation therapy with midostaurin: preliminary results

Number: 4079

Presenter: Roberto Cairoli

Session: 616. Acute myeloid leukemias: investigational therapies, excluding transplantation and cellular immunotherapies: Poster III

Time and location: Monday, December 12, 2022:

6:00–8:00 PM, Hall D (Ernest N. Morial Convention Center)

Learn more at oncomine.com/ash2022